Healthcare provider profile · identity verified

Zulehuma Rather, MD

Internal Medicine · DOVER, DE · NPI 1386966083

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	213	62
Atorvastatin Calcium	Atorvastatin Calcium	205	70
Losartan Potassium	Losartan Potassium	182	51
Metformin Hcl	Metformin Hcl	177	50
Lisinopril	Lisinopril	172	50
Hydrochlorothiazide	Hydrochlorothiazide	163	49
Levothyroxine Sodium	Levothyroxine Sodium	144	40
Omeprazole	Omeprazole	123	44
Gabapentin	Gabapentin	101	26
Rosuvastatin Calcium	Rosuvastatin Calcium	99	32
Simvastatin	Simvastatin	98	28
Meloxicam	Meloxicam	97	33
Pantoprazole Sodium	Pantoprazole Sodium	89	27
Metoprolol Succinate	Metoprolol Succinate	72	20
Potassium Chloride	Potassium Chloride	71	19
Furosemide	Furosemide	70	18
Trazodone Hcl	Trazodone Hcl	70	19
Albuterol Sulfate Hfa	Albuterol Sulfate	68	29
Montelukast Sodium	Montelukast Sodium	68	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	66	31
Fluticasone Propionate	Fluticasone Propionate	62	26
Famotidine	Famotidine	61	16
Zolpidem Tartrate	Zolpidem Tartrate	61	suppressed
Tizanidine Hcl	Tizanidine Hcl	60	20
Carvedilol	Carvedilol	56	17
Metoprolol Tartrate	Metoprolol Tartrate	51	13
Pravastatin Sodium	Pravastatin Sodium	50	16
Ibuprofen	Ibuprofen	46	22
Sertraline Hcl	Sertraline Hcl	40	suppressed
Allopurinol	Allopurinol	35	11
Dicyclomine Hcl	Dicyclomine Hcl	35	16
Glipizide	Glipizide	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	33	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	33	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	33	suppressed
Diclofenac Sodium	Diclofenac Sodium	30	12
Sumatriptan Succinate	Sumatriptan Succinate	30	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	30	suppressed
Ventolin Hfa	Albuterol Sulfate	30	suppressed
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Ondansetron Hcl	Ondansetron Hcl	29	11
Oxybutynin Chloride Er	Oxybutynin Chloride	29	suppressed
Glimepiride	Glimepiride	28	suppressed
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Atenolol	Atenolol	27	suppressed
Alendronate Sodium	Alendronate Sodium	25	suppressed
Metformin Hcl Er	Metformin Hcl	25	suppressed
Single Use Swab	Alcohol Antiseptic Pads	24	suppressed
Ondansetron Odt	Ondansetron	23	suppressed
Ezetimibe	Ezetimibe	22	suppressed
Betamethasone Valerate	Betamethasone Valerate	20	13
Duloxetine Hcl	Duloxetine Hcl	20	suppressed
Nifedipine Er	Nifedipine	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Solifenacin Succinate	Solifenacin Succinate	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Megestrol Acetate	Megestrol Acetate	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Valsartan	Valsartan	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Meclizine Hcl	Meclizine Hcl	14	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Nexium	Esomeprazole Magnesium	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	12	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error